Unitron Medx SRL
1.0 FTEUnitron Medx reported total assets of 115,784 € at the end of the 2025 financial year (annual accounts filed with the NBB on 06 Jul 2026), with 1 full-time equivalent.
The score of Unitron Medx shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -62 % Total assets +63 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Unitron Medx's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 06 Jul 2026
- Year ended 31 Dec 2024filed on 18 Aug 2025
- Year ended 31 Dec 2023filed on 19 Jun 2024
- Year ended 31 Dec 2022filed on 30 Aug 2023
- Year ended 31 Dec 2021filed on 30 May 2022
Unitron Medx's financial analysis
- Solvency6.4%sector median: 51.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Unitron Medx
Unitron Medx's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0835.668.559
- VAT number
- BE0835668559
- Peppol
- Registered · 0208:0835668559 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 31 Mar 2011
- Registered office
- 9050 Ghent
- Size
- Micro · 1.0 FTE
- Latest accounts
- 2025 · filed on 06 Jul 2026
- Activity
- Manufacture of electronic components (NACE 26110)
Unitron Medx (SRL) has been based in Ghent since 2011, active in: manufacture of electronic components. For 2025, it reports a net loss of 3,587 € and equity of 7,453 €; its revenue is not published. With 1.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 6.4%, below the median of its sector (51.6%).
Companies similar to Unitron Medx
Companies in the same business, of comparable size and area, outside its group.
- PentaSono Manufacture of electronic components Bertem · balance sheet 80,789 €
- DLE Engineering Engineering activities and related technical consultancy Beringen · balance sheet 223,765 €
- D.E.M -Solutions Engineering activities and related technical consultancy Nazareth-De Pinte · balance sheet 196,597 €
- Metec Manufacture of electronic components Zonhoven · balance sheet 156,595 €
- Virenti Manufacture of electronic components Brussels · balance sheet 169,319 €
- Oktow Manufacture of electronic components Izegem · balance sheet 392,847 €
- Klaar Engineering activities and related technical consultancy Tessenderlo-Ham · balance sheet 168,918 €
- Skedia Manufacture of electronic components Sambreville · balance sheet 346,555 €
Frequently asked questions about Unitron Medx
What is the revenue of Unitron Medx?
Unitron Medx files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Unitron Medx?
In Belgium, the VAT number is the company number prefixed with BE: BE0835668559 for Unitron Medx, if the company is VAT-registered. Its company number (CBE) is 0835.668.559.
Where is the registered office of Unitron Medx?
According to the CBE register, the registered office of Unitron Medx is in 9050 Ghent.
What is the equity of Unitron Medx?
At the close of the 2025 financial year, the equity of Unitron Medx amounts to 7,453 €, a solvency of 6.4% of total assets.
How many people work at Unitron Medx?
1.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Unitron Medx?
The register lists 3 active mandates at Unitron Medx. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Unitron Medx
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →